McKinney Capital Management LLC trimmed its holdings in shares of Illumina, Inc. (NASDAQ:ILMN – Free Report) by 42.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 29,955 shares of the life sciences company’s stock after selling 22,094 shares during the quarter. Illumina accounts for approximately 3.0% of McKinney Capital Management LLC’s investment portfolio, making the stock its 9th largest holding. McKinney Capital Management LLC’s holdings in Illumina were worth $8,198,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also made changes to their positions in ILMN. BlackRock Inc. bought a new position in shares of Illumina in the second quarter worth about $3,374,423,000. WCM Investment Management LLC lifted its holdings in Illumina by 45.5% during the 1st quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock valued at $715,579,000 after buying an additional 1,851,848 shares in the last quarter. Primecap Management Co. CA bought a new stake in Illumina during the 2nd quarter valued at about $617,981,000. Janus Henderson Group PLC lifted its holdings in Illumina by 1.4% during the 1st quarter. Janus Henderson Group PLC now owns 2,100,638 shares of the life sciences company’s stock valued at $258,924,000 after buying an additional 29,094 shares in the last quarter. Finally, Southpoint Capital Advisors LP lifted its holdings in Illumina by 20.0% during the 1st quarter. Southpoint Capital Advisors LP now owns 2,100,000 shares of the life sciences company’s stock valued at $258,846,000 after buying an additional 349,536 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors.
Illumina Stock Down 1.2%
NASDAQ:ILMN traded down $2.54 during mid-day trading on Friday, reaching $207.01. The company’s stock had a trading volume of 1,229,158 shares, compared to its average volume of 2,291,458. Illumina, Inc. has a 1 year low of $112.65 and a 1 year high of $309.35. The stock has a fifty day moving average of $249.02 and a 200-day moving average of $179.64. The firm has a market capitalization of $31.30 billion, a PE ratio of 35.63, a price-to-earnings-growth ratio of 2.84 and a beta of 1.46. The company has a quick ratio of 2.05, a current ratio of 2.63 and a debt-to-equity ratio of 0.57.
Illumina (NASDAQ:ILMN – Get Free Report) last posted its earnings results on Thursday, October 29th. The life sciences company reported $1.62 EPS for the quarter, beating analysts’ consensus estimates of $1.36 by $0.26. Illumina had a net margin of 19.72% and a return on equity of 28.38%. The business had revenue of $1.17 billion for the quarter, compared to the consensus estimate of $1.15 billion. During the same quarter last year, the firm posted $1.34 EPS. The company’s revenue for the quarter was up 4.2% on a year-over-year basis. Equities research analysts forecast that Illumina, Inc. will post 5.43 earnings per share for the current year.
Wall Street Analysts Forecast Growth
A number of equities analysts have commented on the stock. Piper Sandler upped their target price on shares of Illumina from $225.00 to $305.00 and gave the stock an “overweight” rating in a research note on Monday, September 28th. Stifel Nicolaus lifted their price target on shares of Illumina from $155.00 to $225.00 and gave the company a “buy” rating in a research note on Friday, July 31st. JPMorgan Chase & Co. decreased their price target on shares of Illumina from $320.00 to $300.00 and set an “overweight” rating for the company in a research note on Friday, October 30th. Barclays boosted their price target on Illumina from $160.00 to $200.00 and gave the company an “underweight” rating in a report on Wednesday, October 7th. Finally, Deutsche Bank cut Illumina to a “hold” rating in a research note on Wednesday, August 5th. Ten research analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $244.24.
Read Our Latest Stock Analysis on Illumina
Illumina News Roundup
These are some of the ILMN news items that stood out recently:
- Positive Sentiment: An updated valuation estimate raised Illumina’s fair value to $261.45 per share from $248.90, offering a potential upside reference. Illumina Stock Sees Modest Fair Value Lift
- Positive Sentiment: Illumina expanded its molecular residual disease research portfolio with a duplex-sequencing workflow and was selected to provide whole-genome sequencing for Singapore’s SG-INSIGHT study, supporting its clinical oncology and precision-medicine ambitions. Illumina Unveils Duplex Sequencing Workflow for MRD Research
- Neutral Sentiment: Analyst views remain divided, with ratings ranging from Sell to Buy. The reported consensus target is $244.24, while estimates reflect competing expectations for clinical demand and AI-related opportunities versus execution and valuation risks. Analyst Debate on Illumina’s Growth Outlook
Insider Activity
In related news, Director Keith Meister sold 299,336 shares of Illumina stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $217.96, for a total transaction of $65,243,274.56. Following the transaction, the director directly owned 1,409,851 shares of the company’s stock, valued at $307,291,123.96. This trade represents a 17.51% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders have sold 1,881,899 shares of company stock worth $415,905,954 in the last 90 days. 2.90% of the stock is currently owned by company insiders.
Illumina Profile
Illumina, Inc. develops and supplies technologies used to analyze genetic variation and biological function. Its products include next-generation sequencing systems, microarrays, reagents and consumables, as well as software and related services that help customers generate and interpret genomic data. The company’s technology is used in applications such as medical and population research, genetic testing, drug development, and agricultural and environmental studies. Its customers include academic and government research institutions, hospitals and clinical laboratories, biotechnology and pharmaceutical companies, and other organizations around the world.
Read More
- Five stocks we like better than Illumina
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN – Free Report).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.
